Literature DB >> 6238616

Response to aminoglutethimide and cortisone acetate in advanced prostatic cancer.

B A Ponder, R J Shearer, R D Pocock, J Miller, D Easton, C E Chilvers, M Dowsett, S L Jeffcoate.   

Abstract

Forty patients with metastatic adenocarcinoma of the prostate were evaluated for response to treatment with aminoglutethimide plus cortisone acetate. All had relapsed from or failed to respond to primary endocrine treatment with orchidectomy or stilboestrol. Nineteen patients (48%) showed subjective response, in most cases relief of bone pain. Side effects limited treatment in only 3 patients. We conclude that aminoglutethimide plus cortisone acetate is a useful addition to the treatment available for this difficult group of patients. The mechanism by which this treatment has a beneficial effect remains unclear.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6238616      PMCID： PMC1977020          DOI： 10.1038/bjc.1984.253

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  25 in total

1.  Regulation of cytoplasmic dihydrotestosterone binding in dog prostate by 17 beta-estradiol.

Authors:  R J Moore; J M Gazak; J D Wilson
Journal:  J Clin Invest       Date:  1979-03       Impact factor: 14.808

2.  Adrenal suppression in the treatment of carcinoma of the prostate.

Authors:  M R Robinson; R J Shearer; J D Fergusson
Journal:  Br J Urol       Date:  1974-10

3.  Bilateral adrenalectomy for palliative treatment of prostatic cancer.

Authors:  E M Mahoney; J H Harrison
Journal:  J Urol       Date:  1972-12       Impact factor: 7.450

4.  Pituitary irradiation in advanced carcinoma of the prostate: analysis of 100 cases.

Authors:  J D Fergusson; W F Hendry
Journal:  Br J Urol       Date:  1971-10

5.  Inhibition of adrenal corticosteroid synthesis by aminoglutethimide: studies of the mechanism of action.

Authors:  R N Dexter; L M Fishman; R L Ney; G W Liddle
Journal:  J Clin Endocrinol Metab       Date:  1967-04       Impact factor: 5.958

6.  Study of steroid-protein binding by a novel "two-tier" column employing Cibacron Blue F3G-A-Sepharose 4B. I-Sex hormone binding globulin.

Authors:  M J Iqbal; M W Johnson
Journal:  J Steroid Biochem       Date:  1977-09       Impact factor: 4.292

7.  Half and total body radiation for carcinoma of the prostate.

Authors:  L M Epstein; B H Stewart; A R Antunez; C B Hewitt; R A Straffon; D K Montague; R S Dhaliwal; G Jelden
Journal:  J Urol       Date:  1979-09       Impact factor: 7.450

8.  Serum aminoglutethimide levels: studies of serum half-life, clearance, and patient compliance.

Authors:  F T Murray; S Santner; E Samojlik; R J Santen
Journal:  J Clin Pharmacol       Date:  1979 Nov-Dec       Impact factor: 3.126

Review 9.  Aminoglutethimide medical adrenalectomy for advanced prostatic carcinoma.

Authors:  E J Sanford; J R Drago; T J Rohner; R Santen; A Lipton
Journal:  J Urol       Date:  1976-02       Impact factor: 7.450

10.  Transsphenoidal hypophysectomy for disseminated carcinoma of the prostate gland. Results in 53 patients.

Authors:  G T Tindall; N S Payne; D W Nixon
Journal:  J Neurosurg       Date:  1979-03       Impact factor: 5.115
View more
  7 in total

Review 1.  Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer.

Authors:  P E Lønning; S Kvinnsland
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

Review 2.  Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer.

Authors:  L R Wiseman; D McTavish
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

Review 3.  Aromatase inhibitors in malignant diseases of aging.

Authors:  D C Johannessen; P E Lønning
Journal:  Drugs Aging       Date:  1992 Nov-Dec       Impact factor: 3.923

4.  The effects of aminoglutethimide and hydrocortisone, alone and combined, on androgen levels in post-orchiectomy prostatic cancer patients.

Authors:  M Dowsett; R J Shearer; B A Ponder; P Malone; S L Jeffcoate
Journal:  Br J Cancer       Date:  1988-02       Impact factor: 7.640

5.  Aromatase inhibition in advanced prostatic cancer: preliminary communication.

Authors:  R J Shearer; J H Davies; M Dowsett; P R Malone; A Hedley; D Cunningham; R C Coombes
Journal:  Br J Cancer       Date:  1990-08       Impact factor: 7.640

6.  Aromatase inhibition: 4-hydroxyandrostenedione (4-OHA, CGP 32349) in advanced prostatic cancer.

Authors:  J H Davies; M Dowsett; S Jacobs; R C Coombes; A Hedley; R J Shearer
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

Review 7.  Roles for the backdoor pathway of androgen metabolism in prostate cancer response to castration and drug treatment.

Authors:  Michael V Fiandalo; John Wilton; James L Mohler
Journal:  Int J Biol Sci       Date:  2014-06-03       Impact factor: 6.580
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.